The Kaiser Permanente-backed medical device producer upscaled its initial public offering to $64.4m after the underwriters took up the over-allotment option.
Vapotherm, the US-based respiratory distress treatment provider backed by healthcare consortium Kaiser Permanente, has closed its initial public offering at $64.4m after the underwriters took up the over-allotment option.
The company raised an initial $56m when it floated on the New York Stock Exchange on Wednesday last week, pricing its shares at the bottom of the offering’s $14 to $16 range.
Joint book-running managers BofA Merrill Lynch and William Blair, lead manager Canaccord Genuity and co-manager BTIG bought an…
